Pacific Biosciences of California Inc (NASDAQ:PACB) shares, rose in value, with the stock price up by 1.47% to the previous day’s close as strong demand from buyers drove the stock to $1.38.
Actively observing the price movement in the last trading, the stock closed the session at $1.36. The value of beta (5-year monthly) was 1.83. Referring to stock’s 52-week performance, its high was $14.55, and the low was $1.25. On the whole, PACB has fluctuated by -60.80% over the past month.
With the market capitalization of Pacific Biosciences of California Inc currently standing at about $375.75 million, investors are eagerly awaiting this quarter’s results, scheduled for Apr 30, 2024 – May 06, 2024.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that PACB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PACB currently trading nearly -49.40% and -64.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 19.95, while the 7-day volatility ratio is showing 12.10% which for the 30-day chart, stands at 11.88%. Furthermore, Pacific Biosciences of California Inc (PACB)’s beta value is 1.99, and its average true range (ATR) is 0.31.
A comparison of Pacific Biosciences of California Inc (PACB) with its peers suggests the former has fared considerably weaker in the market. PACB showed an intraday change of 1.47% in last session, and over the past year, it shrunk by -86.48%%.
Data on historical trading for Pacific Biosciences of California Inc (NASDAQ:PACB) indicates that the trading volumes over the past 3 months, they’ve averaged 9.79 million. According to company’s latest data on outstanding shares, there are 267.74 million shares outstanding.
Nearly 6.08% of Pacific Biosciences of California Inc’s shares belong to company insiders and institutional investors own 100.06% of the company’s shares. The stock has fallen by -85.93% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PACB stock heading into the next quarter.
